Table 2.
Characteristics of patients treated with OARExtreme-sparing SBRT.
| Patient characteristics | Number |
|---|---|
| Total patients | 60 |
| Total sites treated | 69 |
| Patients with regional recurrence requiring re-SBRT |
9 |
| Gender | |
| Male | 39 (70%) |
| Female | 21 (30%) |
| Median age in years (range) | 70 (48–88) |
| Median initial radiation dose in Gray | 63.6 |
| Median interval from prior irradiation in months | 16.5 |
| Surgery at recurrence | 32 (53%) |
| Concurrent systemic therapy with SBRT | 39 (57%) |
| Carboplatin/paclitaxel | 20 |
| Cetuximab | 6 |
| Carboplatin/paclitaxel/cetuximab | 1 |
| Cisplatin | 3 |
| Carboplatin/pemetrexed | 2 |
| Other/unknown | 7 |
| Histology | |
| Squamous cell carcinoma | 51 (74%) |
| Adenocarcinoma | 4 (6%) |
| Other | 14 (20%) |
| SBRT site | |
| Aerodigestive tract (AD) | 30 (43%) |
| Lateral neck (LAT) | 15 (22%) |
| Skull base | 24 (35%) |
| SBRT dosimetry | |
| Median treatment volume in cc | 61.0 |
| Median V90 | 98.4% |
| Median D90 | 99.0% |
| Median follow-up in months | 9.3 |